Apatinib Plus Irinotecan as Second-line Treatment in AGC or EGJA

NCT03116555 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Gastric Adenocarcinoma

Interventions

DRUG: Apatinib
DRUG: Irinotecan

Sponsor

China Medical University, China

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]